Dr. Gary L. Mcphail, M.D.
Pediatric Pulmonology (Pediatric Pulmonology Physician)
At a glance
- Medical school
- University of Texas Southwestern Medical School at Dallas (2001)
- Years since graduation
- 25
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2001Medical school: University of Texas Southwestern Medical School at Dallas
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Pulmonology Physician primary
OH license 35.084588
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Children's Hospital Medical Center (711 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $17.59 in total to this clinician.
| Alcresta Therapeutics, Inc. | $17.59 |
|---|
| Food and Beverage | $17.59 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 1 companies. The companies reported $331,176 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Study Evaluating the Pharmacokinetics, Safety, and Tolerability of VX-121/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Through 11 Years of Age
Vertex Pharmaceuticals Incorporated - A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor Triple Combination Therapy in Cystic Fibrosis Subjects 1 Year of Age and Older
Vertex Pharmaceuticals Incorporated - A Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis Less Than 12 Months of Age
Vertex Pharmaceuticals Incorporated - A Non-Interventional Study Evaluating the Impact of TRIKAFTA Initiation on 2- to 5-Year-Olds With Cystic Fibrosis and Their Caregivers in a Real-World Setting
Vertex Pharmaceuticals Incorporated
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.